Todos Medical Appoints Greg Meiselbach as Vice Pre
Post# of 30027
(Total Views: 380)
Posted On: 03/08/2022 6:16:57 PM
Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs
New York, NY, and Tel Aviv, ISRAEL, March 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has appointed Greg Meiselbach as Vice President of Government Affairs. Mr. Meiselbach brings over 10 years of government and business development experience in the biotechnology industry to Todos. Mr. Meiselbach will focus on liaising with governments regarding the deployment of Tollovir™, Tollovid® and Videssa®.
“We see significant potential to bring Tollovir to governments as a key solution for hospital overutilization which is currently the biggest risk to national healthcare systems,” said Greg Meiselbach, VP of Government Affairs at Todos. “Governments spanning the globe have realized the importance of bringing oral antivirals into the market. Tollovir has the potential to dramatically lower the stress on strained healthcare systems by decreasing length of hospital stays for COVID patients by potentially allowing patients to complete treatment at home, and reducing the drug administration burden that hospitals are currently experiencing. We believe Tollovir could be a game changer for many countries that have limited hospital capacity. I’m excited with the opportunity to lead this effort.”
Mr. Meiselbach has a track record of building successful international outreach and business development programs for western companies seeking a foothold in emerging markets. Most recently, Greg was Head of Healthcare Business Development for Softbank-backed REEF Technology (REEF). Prior to REEF, Mr. Meiselbach was Director for International Affairs at the Biotechnology Innovation Organization (BIO) for five years. In his role, he managed BIO’s international government affairs portfolio for Asia Pacific and worked with BIO’s members to craft international engagement strategies to promote member companies’ business interests abroad. Prior to this, while based out of Singapore, Mr. Meiselbach built and managed the Asia Pacific portfolio of Frontier Strategy Group’s Expert Advisory Network, a broad network of in-market experts, professionals, and former officials who supported Frontier Strategy Group’s clients’ expansion into emerging markets. Greg has traveled abroad extensively and as a child grew up in Tokyo, Japan and Beijing, China. He holds a B.A. in Political Science from Tufts University in Medford, MA and speaks conversational Mandarin.
“As we await the completion of the formation of 3CL Pharma together with NLC Pharma, we are positioning Todos to drive value through our Tollo brand of products as government strategies begin to shift towards reducing infection severity of COVID infection with antivirals. The building blocks of the new strategy are ‘Test to Treat’ programs, for which we are preparing to gather data based on real world evidence to upgrade Tollovid’s regulatory status from dietary supplement to OTC drug targeting adult outpatient treatment, pediatric outpatient treatment and adult & pediatric Long COVID. In the hospital setting, this new COVID policy aims to limit the potential stress on healthcare systems by monitoring key metrics related to hospital capacity that favorably correlate with the positive data for Tollovir that showed an over 7-day reduction in time to hospital discharge, as well as reduction in rates of deterioration to intubation that stretch ICU capacity,” said Gerald Commissiong, President & CEO of Todos Medical. “It is clear that the most significant direct costs of the pandemic for governments are direct hospitalization costs and the costs of lost productivity due to worker disability with Long COVID. We cannot even begin to quantify the loss of the educational years experienced by children with Long COVID. These are among the litany of problems that this suite of products addresses and forms the basis of 3CL Pharma. Greg will lead the effort to align and formalize our interactions with governments in need of our products.”
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
https://investor.todosmedical.com/news-events...esident-of
New York, NY, and Tel Aviv, ISRAEL, March 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has appointed Greg Meiselbach as Vice President of Government Affairs. Mr. Meiselbach brings over 10 years of government and business development experience in the biotechnology industry to Todos. Mr. Meiselbach will focus on liaising with governments regarding the deployment of Tollovir™, Tollovid® and Videssa®.
“We see significant potential to bring Tollovir to governments as a key solution for hospital overutilization which is currently the biggest risk to national healthcare systems,” said Greg Meiselbach, VP of Government Affairs at Todos. “Governments spanning the globe have realized the importance of bringing oral antivirals into the market. Tollovir has the potential to dramatically lower the stress on strained healthcare systems by decreasing length of hospital stays for COVID patients by potentially allowing patients to complete treatment at home, and reducing the drug administration burden that hospitals are currently experiencing. We believe Tollovir could be a game changer for many countries that have limited hospital capacity. I’m excited with the opportunity to lead this effort.”
Mr. Meiselbach has a track record of building successful international outreach and business development programs for western companies seeking a foothold in emerging markets. Most recently, Greg was Head of Healthcare Business Development for Softbank-backed REEF Technology (REEF). Prior to REEF, Mr. Meiselbach was Director for International Affairs at the Biotechnology Innovation Organization (BIO) for five years. In his role, he managed BIO’s international government affairs portfolio for Asia Pacific and worked with BIO’s members to craft international engagement strategies to promote member companies’ business interests abroad. Prior to this, while based out of Singapore, Mr. Meiselbach built and managed the Asia Pacific portfolio of Frontier Strategy Group’s Expert Advisory Network, a broad network of in-market experts, professionals, and former officials who supported Frontier Strategy Group’s clients’ expansion into emerging markets. Greg has traveled abroad extensively and as a child grew up in Tokyo, Japan and Beijing, China. He holds a B.A. in Political Science from Tufts University in Medford, MA and speaks conversational Mandarin.
“As we await the completion of the formation of 3CL Pharma together with NLC Pharma, we are positioning Todos to drive value through our Tollo brand of products as government strategies begin to shift towards reducing infection severity of COVID infection with antivirals. The building blocks of the new strategy are ‘Test to Treat’ programs, for which we are preparing to gather data based on real world evidence to upgrade Tollovid’s regulatory status from dietary supplement to OTC drug targeting adult outpatient treatment, pediatric outpatient treatment and adult & pediatric Long COVID. In the hospital setting, this new COVID policy aims to limit the potential stress on healthcare systems by monitoring key metrics related to hospital capacity that favorably correlate with the positive data for Tollovir that showed an over 7-day reduction in time to hospital discharge, as well as reduction in rates of deterioration to intubation that stretch ICU capacity,” said Gerald Commissiong, President & CEO of Todos Medical. “It is clear that the most significant direct costs of the pandemic for governments are direct hospitalization costs and the costs of lost productivity due to worker disability with Long COVID. We cannot even begin to quantify the loss of the educational years experienced by children with Long COVID. These are among the litany of problems that this suite of products addresses and forms the basis of 3CL Pharma. Greg will lead the effort to align and formalize our interactions with governments in need of our products.”
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
https://investor.todosmedical.com/news-events...esident-of
(1)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼